Since estrogen (E2) has been ascribed neuroprotective properties (1–3), we sought to explore if selective activation of the estrogen receptor beta (ERβ, Esr2 gene product), a more clinically relevant target than ERα, can be protective against amyloid-related pathology in the AppNL-G-F mouse model of AD. This evidence concerns the gene ESR2 and Alzheimer disease.